Arcus Capital Partners’s Amgen AMGN Stock Holding History

Arcus Capital Partners’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-418	Closed	-$110K	–	130
2022 Q4	$110K	Buy	+418	New	+$112K	0.04%	126

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arcus Capital Partners's AMGN Position: Q1 2023 in Review

Arcus Capital Partners sold out of Amgen (AMGN) in Q1 2023, closing a stake of 418 shares — an estimated $110K sold.

Arcus Capital Partners first reported a position in AMGN in Q4 2022 and held it in 1 quarter. The position peaked at $110K in Q4 2022. 2,435 funds tracked by Wall St. Rank hold AMGN as of Q1 2023.

Arcus Capital Partners reported no remaining Amgen position as of Q1 2023 after selling out during the quarter.
Arcus Capital Partners sold 418 Amgen shares in Q1 2023, an estimated $110K.
Arcus Capital Partners first reported a position in Amgen in Q4 2022 and held it in 1 quarter.
Arcus Capital Partners's Amgen position peaked at $110K in Q4 2022.
2,435 funds tracked by Wall St. Rank held Amgen as of Q1 2023.

Based on Arcus Capital Partners's 13F filing for Q1 2023, filed 9 May 2023.